glp-1 agonists marketing strategies 2025 Australia Receptor Agonist Market Size to Hit USD 2,117.46 Million by 2035 GLP-1 Agonists Weight Loss Drugs
Description
However, medical professionals emphasize the need for careful screening and monitoring to avoid potential risks in non-diabetic use
2023;383 doi: 10.1136/bmj-2022-071027
Cornell S
Boland et al
Cardiovascular Effects GLP-1-based therapies have been associated with slight increases in heart rate, which may be a concern for adolescents with underlying cardiovascular conditions
332,333,334 The NO produced by iNOS, as a free radical, can regulate intracellular signal transduction and modulate the inflammatory response
